transcription-PCR (RT-PCR) analysis was carried out as described previously (4) . The specific primers used for amplification of the TNF-α, IL-6, IL-1β, and β-actin genes were as described previously (30) . The primers for the amplification of RARβ, p21 CIP1 , Cyclin D1, c-Jun, and c-Fos genes are listed in Supplementary Table S1 .
Clinical chemistry. Before sacrifice, the mice were fasted for 6 hours, and at sacrifice, blood samples were collected for assaying the serum concentrations of insulin, glucose, and TNF-α, which was as described previously (4, 29) . The serum TNF-α (Shibayagi; Gunma, Japan) levels were determined using an enzyme immunoassay according to the manufacturers' protocol. Insulin resistance was estimated by determining the insulin sensitivity check index (QUICKI) as follows; QUICKI = 1/[ log(I 0 ) + log(G 0 )], where I 0 is the fasting insulin level and G 0 is the fasting glucose level, which correlates with the glucose clamp method (31) .
Hepatic lipid analysis. Approximately 200 mg of frozen liver was
homogenized, and lipids were extracted using Folch's method (32) . The triglyceride levels in the liver were measured using the triglyceride E-test kit (Wako Pure Chemical Co.; Osaka, Japan) according to the manufacturer's protocol. To visualize the intrahepatic lipids, Sudan III staining was conducted using the standard procedure with frozen sections.
Statistical analysis.
The results are presented as the mean ± SD and were analyzed using the GraphPad Instat software program version 3.05 (GraphPad Software; San Diego, CA) for Macintosh. Differences among the groups were analyzed by either one-way ANOVA or, as required, by two-way ANOVA. When the ANOVA showed a statistically significant effect (P < 0.05), each experimental group was compared with the control group by using the Tukey-Kramer multiple comparisons 
Results
General observations. As shown in Table 1 , no significant differences were observed in the body, kidney, and fat weights among the groups at the end of the study.
A significant decrease in the liver weight was observed in the ACR-treated groups as compared with the basal diet-fed group (P < 0.05 or P < 0.01), irrespective of DEN treatment. Histopathological examination showed the absence of ACR toxicity in the liver, kidney, and spleen (data not shown).
Effects of ACR on DEN-induced liver tumorigenesis in db/db mice. Table   2 summarizes the incidence and multiplicity of liver neoplasms (adenoma and HCC)
and FCA in the mice from all groups. FCA developed in the livers of mice from all groups, irrespective of DEN treatment. On the other hand, liver cell adenomas only developed in the DEN-treated db/db mice. HCCs also developed in all DEN-treated groups, however, the incidence (10% in each group) wan not high. These findings might be associated with experimental protocol because the duration of the experiments (41 weeks) was sufficient to develop adenoma but not HCC. In mice treated with either dose (0.03% and 0.06%) of ACR, the incidence (P < 0.01 in each comparison) and multiplicity of adenoma (P < 0.05 or P < 0.01) were significantly inhibited compared to ACR-untreated mice. The number of FCA was also significantly decreased by ACR treatment, irrespective of DEN treatment (P < 0.001 or P < 0.05). results of the present study clearly indicated that ACR also effectively prevents the development of obesity-related liver cell adenomas, and these effects are associated with improvement of hepatic steatosis and insulin resistance. Therefore, the findings of the present study, together with the results of previous studies using BCAA (3, 4) , suggest that improvement of metabolic abnormalities by pharmaceutical or nutritional intervention might be an effective strategy for inhibiting obesity-related liver tumorigenesis.
Several biological effects of ACR are relevant to the prevention of obesity-related hepatotumorigenesis. First, it should be noted that ACR inhibits RXRα phosphorylation by suppressing the Ras-ERK signaling pathway in the livers of DEN-treated db/db mice. These findings are consistent with those of previous in vitro studies (15, 23, 24) , but this is the first in vivo experiment, and the results seem to be Next, the effects of ACR in improving hepatic steatosis and insulin resistance, both of which accelerate HCC development (7-9), is discussed. These effects might also be associated with RXRα dephosphorylation since RXR can control insulin sensitization and lipid metabolism by forming a heterodimer with peroxisome proliferator-activated receptor (PPAR), an important molecule in the regulation of lipid homeostasis and energy metabolism (40) . This speculation is interesting because the inhibition of RXRα phosphorylation and the activation of the RXR/PPAR heterodimer are also activities that cooperatively inhibit the growth of cancer cells (41) . In addition, ACR might improve these metabolic abnormalities by activating AMPK, which increases glucose uptake and fatty acid oxidation but decreases fatty acid synthesis (33) .
Cancer Research. Pitavastatin, a lipophilic statin, was found to prevent obesity-and diabetes-related colon carcinogenesis in mice by activating AMPK in the colonic mucosa (29) . These reports suggest the possibility that activation of AMPK by ACR aided in suppressing the development of obesity-related liver cells adenomas, as observed in the present study.
Insulin resistance and lipid accumulation in the liver produce inflammatory changes in the liver (7-9). ACR might decrease the serum levels of TNF-α and the expression levels of TNF-α, IL-6, and IL-1β mRNA in the livers of experimental mice by improving hepatic steatosis and insulin resistance. These findings are significant because obesity-related HCC development clearly depends on enhanced production of TNF-α and IL-6, which cause hepatic inflammation and activate ERK and Stat3 (34).
TNF-α, which lies at the core of the association between obesity and insulin resistance (46) , contributes to obesity-induced IL-6 production and hepatocarcinogenesis (34) .
IL-6 is a major Stat3 activator in the liver, and the activation of the IL-6-Stat3 axis plays a critical role in HCC development (47, 48) . In addition, uncontrolled activation of the Ras-ERK and Jak-Stat pathways is essential for HCC development (49) . In the present study, ubiquitous activation of Ras-ERK signaling presumably caused accumulation of 
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